Track topics on Twitter Track topics that are important to you
NitroMed, Inc. of Lexington, Massachusetts is a research-based emerging pharmaceutical company and the maker of BiDil, an orally administered medicine available in the United States for the treatment of heart failure in self-identified black patients. In this population, BiDil is indicated as an adjunct to current standard therapies such as ACE inhibitors and/or beta blockers. BiDil was approved by the U.S. Food and Drug Administration, primarily on the basis of efficacy data from the Company's landmark A-HeFT (African American Heart Failure Trial) clinical trial.
45 Hayden Avenue
United States of America
BiDil (isosorbide dinitrate and hydralazine hydrochloride)Tablets
NitroMed, Inc. of Lexington, Massachusetts is a research-based emerging pharmaceutical company and the maker of BiDil, an orally administered medicine available in the United States for the treatment ...
HealthCare Ventures is a leading venture capital firm specializing in life science industry investing. At HealthCare Ventures we concentrate our investment dollars on life science companies showing hi...
We have published hundreds of NitroMed news stories on BioPortfolio along with dozens of NitroMed Clinical Trials and PubMed Articles about NitroMed for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of NitroMed Companies in our database. You can also find out about relevant NitroMed Drugs and Medications on this site too.